Anti-CD38 Antibody Treating Evans Syndrome

This trial is testing an anti-CD38 antibody treatment for people with Evans syndrome — a rare autoimmune condition where the immune system attacks its own red blood cells and platelets at the same time, causing anemia and bleeding risk. This study targets people whose disease has not responded to standard treatments. **You may be eligible if...** - You are 18 or older - You have been diagnosed with primary Evans syndrome - Your blood counts are significantly low (platelets <30 or hemoglobin <100g/L, or you have symptomatic anemia) - You have not responded to or have relapsed after corticosteroids and at least one second-line treatment - Your immune system is actively attacking red blood cells (positive DAT test, active hemolysis) - Your liver, kidney, and heart function are within acceptable limits **You may NOT be eligible if...** - You have secondary Evans syndrome (caused by another condition) - You have previously received anti-CD38 antibody therapy - You have another serious uncontrolled disease (e.g., organ failure or active cancer) - You recently used certain immunosuppressive treatments without adequate washout time Talk to your doctor to see if this trial is right for you.